Explore Video

Dr. Enrique Grande describes case scenario of patient with prostate cancer with high volume
high grade tumor (Gleason 9, 4+5)

Anemia is common feature of MDS with 90% patients having anemia at diagnosis or initial presentation. Anemia not only impacts quality of life but is also prognostic in nature.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

View comprehensive coverage of Breast Cancer from ESMO 2022

Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.

Toripalimab, a PD-1 inhibitor, has emerged as a promising treatment for metastatic or locally advanced recurrent NPC. Toripalimab can significantly improve response rates and prolong survival in patients who have progressed on previous therapies

Treating relapsed or refractory multiple myeloma (RRMM) can be complex and typically involves a combination of therapies based on the patient's previous treatments, overall health, and specific disease characteristics.

In real-world settings, Palbociclib-based combination therapy demonstrates improved progression-free survival and clinical benefit rates compared to endocrine monotherapy in HR+/HER2- advanced breast cancer.

Maintenance therapy with Midostaurin in AML patients with FLT3 mutations has shown potential in improving event-free survival and reducing relapse risk.

EHA 2022 saw exciting progress particularly from the perspective of Bispecific Antibodies showing encouraging response rates in relapsed / refractory setting of Multiple Myeloma.